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Aims: Recent studies in arrhythmogenic right ventricular cardiomyopathy (ARVC) patients 
have drawn attention to atrial fibrillation (AF) as an arrhythmic manifestation of ARVC and 
as an indicator of atrial involvement in the disease progression. We aimed to assess the 
prevalence of AF in the Scandinavian cohort of ARVC patients and to evaluate its 
association with disease clinical manifestations.  
Methods: Study sample comprised of 293 definite ARVC patients by 2010 Task Force 
criteria (TFC2010) and 141 genotype-positive family members (total n=434, 43% females, 
median age at ARVC diagnosis 41 years [interquartile range (IQR) 28-52 years]). ARVC 
diagnostic score was calculated as the sum of major (2 points) and minor (1 point) criteria 
in all categories of the TFC2010.  
Results: AF was diagnosed in 42 patients (10%): in 41 patients with definite ARVC 
diagnosis (14%) vs in one genotype-positive family member (1%), p<0.001. The median age 
at AF onset was 51 (IQR 38-58) years. The prevalence of AF was related to the ARVC 
diagnostic score: it significantly increased starting with the diagnostic score 4 (2% in those 
with score 3 vs 13% in those with score 4, p=0.023) and increased further with increased 
diagnostic score (Somer's d value is 0.074, p<0.001).  
Conclusion: AF is seen in 14% of definite ARVC patients and is related to the severity of 
disease phenotype thus suggesting AF being an arrhythmic manifestation of this 








Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an  inherited cardiomyopathy 
characterized by fibro-fatty replacement of the myocardium and a high degree of electric 
instability.[1] Right ventricular  (RV) dysfunction and ventricular arrhythmias are common 
in ARVC patients, and there is an increased risk of sudden cardiac death.[2, 3] However, the 
phenotype of the disease is highly variable ranging from asymptomatic cases to those with 
life-threatening ventricular arrhythmias. While studies of arrhythmic substrate in ARVC has 
understandably been focused on the risk of life-threatening ventricular arrhythmias, recent 
studies have drawn attention to atrial fibrillation (AF) that appears to have high prevalence 
among ARVC patients.[4-6]  
The underlying mechanisms behind AF development in ARVC remain unclear. 
Hemodynamic consequences of the RV contractile dysfunction may contribute to right atrial 
overload, increased stretch and development of fibrosis in the atrial walls.[7] Left ventricular 
(LV) involvement in the disease leading to systolic dysfunction may also be associated  with 
complications such as AF and thromboembolic events.[2]  On the other hand,  it has been 
suggested that development of atrial myocardial substrate in ARVC may be driven by 
genetically determined desmosomal dysfunction.[8] It is possible that involvement of atrial 
myocardium leading to atrial dilatation[5] and AF is caused by the same mechanisms as 
fibrotic replacement of myocardium in the right ventricular walls and takes place in a parallel 
with involvement of ventricular myocardium.  
We aimed to assess the prevalence of atrial fibrillation (AF) as an indicator of atrial 
involvement in the disease progression in a large contemporary cohort of patients with  




Material and methods 
The Nordic ARVC Registry (www.arvc.dk) was launched in June 2010 and has been 
recruiting patients with ARVC previously diagnosed using 1994 TFC and followed in eight 
tertiary care centers in Denmark, Norway or Sweden, covering a population of 
approximately 14 million.[9, 10] The registry has also been prospectively including newly 
diagnosed patients after 2010 with definite ARVC according to 2010 Task Force Criteria 
(TFC2010),[11] and their genotype-positive family members. We included all patients who 
met TFC2010 criteria for definite ARVC diagnosis in this study. Genotype-positive family 
members with a borderline or possible ARVC phenotype were considered to be in the 
preclinical phase of the disease. We included  them in the analysis in order to assess the 
association between AF prevalence and clinical characteristics at different stages of disease 
progression.   
We extracted clinical registry data as previously described.[10] Registry captured baseline 
clinical characteristics and data specific for ARVC TFC2010 diagnostic criteria.[11]  
Prospective follow-up information was available until November 2017 when data for the 
current study were retrieved. All analyses were performed using registry data by the time 
point of the last follow-up date.  
AF diagnosis included in the registry was based on the data from patients’ medical records 
as assessed by a principal investigator of the participating site or on AF documentation by 
ECG, Holter or implantable cardioverter-defibrillator (ICD) interrogation data. AF was 
defined when at least one episode lasting 30 seconds or longer was recorded.  
Ventricular tachyarrhythmias were defined as either ECG-verified or captured by ICD 
device diagnostics ventricular tachycardia (VT) and ventricular fibrillation (VF). Historical 
information regarding VT/VF and syncope was retrieved from patients’ medical records.  
Data on hypertension, diabetes, ischemic heart disease, stroke and heart failure by New York 
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Heart Association (NYHA) classification were collected according to the registry protocol.  
All subjects underwent transthoracic echocardiography and parameters included in the TFC 
2010 were recorded. Data on left atrial (LA) and right atrial (RA) measurements were 
extracted from the cardiac ultrasound reports from medical records. Cardiac magnetic 
resonance imaging (MRI) was performed in 286 patients (66%).  
Biopsy and morphometric analyses were performed in 19% of patients.  
For all patients we calculated an ARVC diagnostic score as previously proposed.[5, 12] The 
score is calculated as the sum of major and minor criteria in all categories of the 2010 TFC 
with each major criteria contributing with 2 points and minor criteria contributing 1 point. 
In each subgroup of patients categorized according to the ARVC diagnostic score we 
assessed the prevalence of AF. 
Regional ethics committees approved the Registry. In Denmark, registry studies do not 
require approval from an ethics committee, but approval was obtained from the Danish Data 
Protection Agency. The study complies with the Declaration of Helsinki. 
Statistical methods 
We used Student’s t-test, Wilcoxon rank sum test, Chi-square test, or Fischers exact test to 
compare differences between groups. 
To assess the link between the ARVC diagnostic score and the prevalence of AF we 
performed in the standard fashion receiver operating characteristic (ROC) analysis with the 
estimation of the area under the curve (AUC). Model fit was assessed using Somers' d since 
there was an assumption of dependency (AF prevalence depending on the degree of 
phenotypical manifestations).  
Univariate binary logistic regression analyses were performed to evaluate odds ratios (OR) 
and 95% confidence interval (CI) of the association between  AF and demographic and 
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clinical characteristics including each component of the TFC2010. Variables associated with 
AF at a significant level in the univariate analyses were included in the multivariable  model. 
A two-sided P-value of <0.05 was considered statistically significant. All analyses were 
performed using SPSS Statistics 25 (SPSS Inc, Chicago, Illinois, USA).  
 
Results 
Clinical and genetic assessment of patients. 
We included 434 patients in the study, of which 293 had definite ARVC. Patients 
characteristics are presented in Table 1. Definite ARVC patients more often had heart failure, 
ischemic heart disease, greater LA volume index (LAVI) and RA volume index (RAVI), but 
did not differ in regard to the presence of hypertension, diabetes or stroke.  
A total of 42 (10%) patients had had AF at any time by the date of the last follow-up. Of 
these patients 41 had definite ARVC, whereas one was a genotype-positive family member 
with borderline ARVC. Among definite ARVC patients, the prevalence of AF was 14 %. In 
patients with definite ARVC, 19 patients (6%) had AF prior to ARVC diagnosis and 22 (8%) 
developed AF during follow up after diagnosis. Median age at AF onset was 51 (IQR 38-58) 
years.  
Definite ARVC patients with AF had higher prevalence of hypertension, diabetes, RV 
structural abnormalities, greater LAVI and RAVI than definite ARVC patients without AF. 
Two ARVC patients with AF had ischemic stroke, but none of ARVC patients without AF. 
We found no differences in regard to VT/VF, sustained VT and syncope.    
Genetic testing was performed in 383 subjects: in 242 ARVC patients (83%) and in all 192 
genotype-positive family members, (51 of them with definite ARVC and 141 with borderline 
or possible ARVC). The majority of mutation-positive patients (n=324) carried a mutation 
in the plakophillin-2 (PKP2) gene (n=214, 66%), followed by desmoglein-2 (DSG2, n=63, 
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19%), desmoplakin (DSP, n=38, 12%), desmocolin-2 (DSC2, n=20, 6%), transmembrane 
protein 43 (TMEM43, n=12, 4%) and plakoglobin (JUP, n=4, 1%); 28 patients had mutations 
in two genes (9%).  
Biopsy was performed in 82 patients (19%); in 16 of them (20%) it was taken from the RV 
free wall and yielded findings consistent with major diagnostic criterion in 12 patients 
(75%). Due to the limited data availability, biopsy findings were not included in the 
statistical analysis.    
Association of AF with ARVC phenotype and significant co-morbidities in definite ARVC 
patients  
In the univariate logistic regression analysis (Table 2), age at ARVC diagnosis, male gender, 
hypertension, diabetes, heart failure greater than II class by New-York Heart Association 
classification, ventricular arrhythmias, RV structural abnormalities and LAVI were 
significantly associated with AF. In the multivariable analysis only LAVI and RV structural 
abnormalities remained independently associated with AF.   
Among patients with definite ARVC, the prevalence of AF in patients with major imaging 
diagnostic criteria (n=201) was 17% (n=34) vs 8% (n=7) in those without (n=92), p=0.045.  
Major imaging criteria were found in 34 of 41 definite ARVC patients with AF (83%) vs 
167 of 252 definite ARVC patients without AF (66%), p=0.045. 
AF and ARVC diagnostic score.   
The distribution of AF prevalence in patients according to the ARVC diagnostic score is 
presented in Figure 1. Starting with the diagnostic score 4, which is a threshold for definite 
ARVC diagnosis, the prevalence of AF increased concomitant with the increase in the 
diagnostic score. AUC in ROC analysis was 0.688, p<0.001. There was a positive significant 





We assessed the prevalence of AF and its association with ARVC phenotype prominence in 
a large register-based Scandinavian cohort of patients with definite ARVC by TF2010 and 
their genotype-positive family members. We report that AF is observed in nearly one of 
seven patients with definite ARVC at 50-years of age. The risk of developing AF was 
significantly related to the severity of ARVC phenotype. AF prevalence was at least six-fold 
higher in patients with clinically manifest ARVC than in genotype-positive family members 
with less penetrant disease, which is a novel finding. In the genotype-positive family 
members without clinical signs of ARVC the prevalence of AF was low and corresponded 
to the prevalence reported for the general population at age under 50 years.  
Study cohort 
Most previous studies focusing on atrial arrhythmias in ARVC patients were modest in 
regard to the sample size (n=71)[4]  or included highly selected symptomatic patients with 
VT with number of patients varying from 36[6] to 72.[13] 
Our study sample size is comparable with the Johns Hopkins ARVC registry report which 
was the first large scale study focusing on atrial arrhythmias in the context of ARVC and 
included 248 patients with definite ARVC.[5]  We performed our study on 293 definite 
ARVC patients, but, in contrast to the Johns Hopkins ARVC registry,[5]  also included 141 
genotype-positive family members without definite ARVC to assess whether AF was the 
early manifestation of the disease and to compare AF prevalence in them to the AF 
prevalence in patients with ascertained clinical diagnosis. 
Prevalence of AF in ARVC 
One of the most important findings of our study is the observed AF prevalence of 14% 
among definite ARVC patients of a relatively young age.  
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According to the epidemiological data from the same geographical region, such as the 
Malmo Diet and Cancer Study,[14] the prevalence of AF for the age 50-55 years is reported 
to be as low as 1%,  or even lower for the age range 40-50 years, in which most of our 
patients were diagnosed with ARVC, that might be the cause of clearly premature AF.  
Notably, in our study the prevalence of AF in genotype-positive family members without 
prominent disease was 1 of 141 (0.7%), which is similar to the prevalence in the general 
population.  
The higher age-specific prevalence of AF in ARVC patients than in the general population 
has been observed in previous ARVC studies on atrial arrhythmias. The prevalence of atrial 
arrhythmias ranged from 14% in definite ARVC patients [5]  to 24% in ARVC patients with 
VT [13] and up to 42 % in ARVC patients who underwent ablation for VT.[6] The difference 
in the prevalence of atrial arrhythmias might be explained by the patient selection since the 
highest prevalence was observed among patients with VT representing patients with severe 
disease phenotype, though in our study we did not observe any relation between AF and VT.  
Our data from the unselected cohort of Scandinavian patients with ARVC  are in line with 
the data from the Johns Hopkins ARVD/C registry.[5]  An  AF prevalence of 14-times higher 
than the reported prevalence in the general population of the same age indicates that AF 
might be considered as one of the arrhythmic manifestations of ARVC. 
Pathophysiologic mechanisms of AF in ARVC patients. 
The mechanisms underlying AF development in ARVC patients are not fully understood. 
Though we could not exclude the role of pulmonary vein triggers in the development of AF, 
mechanistically, two principal mechanisms leading to development of AF in ARVC can be 
considered.  
According to the current pathophysiological paradigm, ARVC is considered to be a disease 
of the cardiac desmosome.[15] Desmosomes are found throughout the cardiac myocardium, 
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including atrial myocardium.[16] There are anecdotal reports documenting atrial myocardial 
involvement in ARVC patients based on postmortem case series[17] and supported by 
animal studies.[8],[18] The evidence of altered electrical conduction within the atria of 
ARVC patients has also previously been demonstrated.[19]  It is therefore plausible to 
suggest that atrial involvement in the disease progression may be driven by the same 
desmosomal dysfunction leading to fibrotic transformation of atrial myocardium as in the 
ventricles, which is likely to be causally related to development of AF.  
On the other hand, AF can develop as a result of hemodynamic consequences of RV 
dysfunction, that leads to RA enlargement in ARVC patients. The association between AF 
and RA enlargement has been reported previously,[7] however, we did not find any 
association of AF with RA enlargement in our study. Furthermore, the prevalence of AF 
reached 8% in patients with definite ARVC diagnosis without advanced RV or LV 
dysfunction which indirectly supports the notion of AF being a consequence of atrial 
structural remodeling not related to atrial overload caused by ventricular malfunction, but 
most likely due to atrial fibrosis. 
In our study AF was associated with the LA size, the association which in ARVC patients is 
not fully understood. As LAVI did not express any significant association with LV 
dysfunction in our study, the relationship between the AF and LA enlargement in the context 
of ARVC resemble the one observed in patients with non-valvular AF suggesting that the 
arrhythmia in patients with ARVC maybe LA driven. On the other hand, LA enlargement  
may also be a result rather than a cause of AF, since LA enlargement is a known secondary 
effect of AF. [20]  However, in our study ARVC patients with AF more often had arterial 
hypertension and diabetes than their non-arrhythmic counterparts. Both hypertension and 
diabetes are known to be associated with LA dilation. Although neither of these factors 
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remained an independent AF predictor in the multivariate analysis, their contribution to an 
increase LA size and as a consequence the occurrence of AF cannot be excluded.  
Early onset AF observed in our ARVC cohort suggests that cardiomyopathy-associated 
structural remodeling of atrial myocardium may occur at young age and predispose to AF 
breakthrough. 
AF and ARVC phenotype 
To the best of our knowledge, we are the first to report the association between AF and 
phenotypical manifestations of ARVC. We used the diagnostic score in the same way as 
earlier reported,[5, 12] as a measure of ARVC phenotype severity, and found that AF 
prevalence was significantly associated with the score thus indicating that the more advanced 
is the disease phenotype, the higher is the prevalence of AF.  
AF was strongly linked to disease severity and was found primarily among our patients with 
definite ARVC diagnosis. Among genotype-positive family members with borderline or 
possible ARVC only one had AF which indicates the possibility of atrial and ventricular 
expression taking place in a parallel. Furthermore, the described association of AF and RV 
structural abnormalities in our study population supports the hypothesis of AF being a 
phenotypical manifestation of the disease.  
Clinical perspective 
The high prevalence of AF in ARVC patients indicates a need for alertness among clinicians 
to rule out AF as not all palpitations in ARVC patients are VT. Furthermore, though ARVC 
patients are usually young and do not have cardiovascular comorbidities,  the detection of 
AF may lead to prescription of anticoagulant therapy if additional cardiovascular risk factors 
are present. Notably, 2 of 41 (5%)  ARVC patients with AF in our study had ischemic stroke 
at age 33 and 78 years respectively. Given the consistently reported high prevalence of AF 
in ARVC patients at young age and a possibility of under-diagnosis of AF in mildly 
 15 
symptomatic patients, our data indicate the need for systematic screening for AF among 
ARVC patients. 
Study limitation 
Though Nordic ARVC Registry is a prospective observational study with AF as a 
prespecified reportable clinical event, information regarding AF prior to ARVC diagnosis 
and inclusion in the registry was collected retrospectively, which is a limitation of our study. 
Furthermore, due to the observational nature of our study, we did not perform a systematic 
screening for AF, which may have led to some asymptomatic AF cases being undiagnosed 
in genotype-positive family members without clinical signs of ARVC, in which follow-up 
could be less stringent and who did not have ICD. However, the majority of patients with 
definite ARVC were implanted with ICD and we had a possibility to detect asymptomatic 
AF episodes using implantable device diagnostics thus coming closer to the real AF 
prevalence among definite ARVC patients.  
Conclusion 
AF is common in patients with definite ARVC and is related to the disease severity thus 
suggesting AF being an arrhythmic manifestation of this cardiomyopathy. Out data suggest 
atrial myocardial involvement in the disease progression.  
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Table 1. Clinical characteristics of patients from the Nordic Arrhythmogenic right ventricular 
cardiomyopathy (ARVC) Registry with Definite ARVC (TF2010) or genetic positive family 

























Follow-up time in years, meanstd 96 107 73 0.003 117 107 0.131 
Female gender, n (%) 186 (43) 102 (35) 84 (60) <0.001 7 (17) 95 (38) 0.013 
Probands, n (%) 226 (52) 213 (73) 13 (9) <0.001 6 (15) 74 (29) 0.058 
Mutation positive, n (%) 324 (75) 183 (63) 141 (100) <0.001 25 (61) 158 (63) 0.863 
Definite ARVC, n (%) 293 (68) - - - - -   
Borderline ARVC, n (%) 58 (13) - - - - -   
Possible ARVC, n (%) 83 (19) - - - - -   
Age at ARVC diagnosis, median (IQR) 41 (28-52) 41 (30-52) 43 (25-52) 0.676 42 (35-57) 40 (29-51) 0.050 
Any VT/VF, n (%) 223 (51) 212 (72) 11 (8) <0.001 33 (81) 179 (71) 0.260 
Sustained VT, n (%) 135 (31) 135 (46) 0 (0) <0.001 24 (59) 111 (44) 0.093 
Syncope, n (%) 28 (7) 24 (7) 4 (3) 0.037 4 (10) 20 (8) 0.757 
ICD, n (%) 213 (49) 213 (73) 0 (0) <0.001 34 (83) 179 (71) 0.132 
Hypertension, n (%) 36 (8) 28 (10) 8 (6) 0.262 9 (23) 19 (8) 0.006 
Ischemic stroke, n (%) 3 (0.7) 2 (0.7) 1 (0.7) 1.000 2 (5) 0 (0) 0.018 
Diabetes, n (%) 13 (3) 9 (3) 4 (3) 1.000 4 (10) 5 (2) 0.023 
Ischemic heart disease, n (%) 14 (3) 13 (5) 1 (0.7) 0.044 4 (10) 9 (4) 0.085 
Heart failure >=NYHA II, n (%) 39 (9) 37 (13) 2 (1) <0.001 8 (20) 29 (12) 0.201 
Right ventricular structural abnormalities 
major, n (%) 
201 (46) 201 (67) 0 (0) <0.001 34 (83) 167 (66) 0.045 
Right ventricular structural abnormalities 
minor, n (%) 
20 (5) 20 (7) 0 (0) <0.001 0 (0) 20 (8) 0.088 
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Std – standard deviation, IQR – interquartile range 25%-75%, VT – ventricular tachycardia, VF – ventricular 
fibrillation, ICD – implantable cardioverter-defibrillator, NYHA – New York Heart Association 
classification, MRI – magnetic resonance imaging.  
Left ventricular ejection fraction, mean±std 56±8 54±9 59±5 <0.001 54±9 56±9 0.260 
Left atrial volume index, ml/m2, mean±std 29±10 30±10 26±8 0.002 37±12 29±10 <0.001 
Right atrial volume index, ml/m2, mean±std 32±19 36±21 23±7 <0.001 35±18 36±21 0.811 
Cardiac MRI performed 286 (66) 214 (73) 72 (51) <0.001 29 (71) 185 (73) 0.708 
Right ventricular ejection fraction (MRI), 
mean±std 
45±12 42±12 54±7 <0.001 39±14 42±11 0.288 
Repolarization abnormalities major, n (%) 153 (35) 153 (52) 0 (0) <0.001 18 (44) 135 (54) 0.312 
Repolarization abnormalities minor, n (%) 38 (9) 32 (11) 6 (4) 0.028 2 (5) 30 (12) 0.279 
Depolarization abnormalities major, n (%) 21 (5) 21 (7) 0 (0) <0.001 4 (10) 17 (7) 0.511 
Depolarization abnormalities minor, n (%) 192 (44) 158 (54) 34 (24) 0.028 19 (46) 139 (55) 0.315 
Arrhythmias major, n (%) 83 (19) 83 (28) 0 (0) <0.001 13 (32) 70 (28) 0.581 
Arrhythmias minor, n (%) 256 (59) 238 (81) 18 (13) <0.001 34 (83) 204 (81) 1.000 
Holter performed, n (%) 342 (79) 225 (77) 117 (83) 0.168 26 (63) 199 (70) 0.044 
Ventricular extrasystoles, mean n ±std 2055±4542 3185±5431 557 ±2256 <0.001 1946 ±5622 3316±2923 0.408 
Family history major, n (%) 335 (77) 194 (66) 141 (100) <0.001 26 (63) 168 (67) 0.723 
Family history minor, n (%) 9 (2) 9 (3) 0 (0) 0.035 0 (0) 9 (4) 0.618 
ARVC diagnostic score, meanstd 5±2 6±2 2±1 <0.001 6±2 6±2 0.774 
 21 
Table 2. Logistic regression analysis showing the association clinical characteristics of 
definite ARVC patients and carriers of genetic mutation with atrial fibrillation.  
  OR 95% CI p value 
Univariate logistic regression  
Age at diagnosis 1.02 1.00-1.04 0.037 
VT/VF  4.57 2.06-10.11 <0.001 
Sustained VT  3.37 1.76-6.46 <0.001 
Syncope  1.91 0.40-9.02 0.414 
Male gender 4.20 1.82-9.69 0.001 
Hypertension 3.81 1.65-8.681 0.002 
Diabetes 4.59 1.35-15.66 0.015 
Ischemic heart disease 0.69 0.45-1.07 0.098 
Heart failure >=NYHA II 2.74 1.17-6.43 0.021 
Left atrial volume index 1.08 1.04-1.13 <0.001 
Right atrial volume index 1.01 0.99-1.03 0.366 
RV structural abnormalities major 5.73 2.58-12.69 <0.001 
Repolarization abnormalities major 1.43 0.75-2.72 0.280 
Repolarization abnormalities minor 0.49 0.12-2.13 0.345 
Depolarization abnormalities major 2.32 0.74-7.25 0.147 
Depolarization abnormalities minor 1.05 0.55-1.98 0.891 
Arrhythmias major 2.06 1.02-4.17 0.044 
Arrhythmias minor 1.14 0.48-2.73 0.764 
Multivariate logistic regression (final model) 
Age at diagnosis 0.99 0.96-1.02 0.540 
VT/VF  0.70 0.21-2.37 0.564 
Male gender 2.86 0.95-8.65 0.063 
Diabetes 0.93 0.08-11.51 0.955 
Heart failure >=NYHA II 0.60 0.12-3.70 0.543 
Hypertension 3.96 0.96-16.40 0.057 
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Left atrial volume index 1.07 1.03-1.12 0.001 
RV structural abnormalities major 4.47 1.02-19.53 0.047 
 
 OR – odds ratio, CI – confidence interval, VT – ventricular tachycardia, VF – ventricular fibrillation, NYHA 
– New York Heart Association classification. 
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Figure. Prevalence of atrial fibrillation (AF) among patients with arrhythmogenic right 
ventricular cardiomyopathy (ARVC) diagnosis and carriers of disease-causing genetic 
variants according to the ARVC diagnostic score based on assignment of 1 point for a 
minor diagnostic criterion and 2 points for a major diagnostic criterion. The lowest score of 
2 corresponds to mutation-carrying status without other disease manifestations (a major 
diagnostic criterion). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
